Want to see CON full AI Analyst Report?
EarningsQ2 2026 Earnings Report
CON Q2 2026 EPS Results
Actual EPS$0.52
Consensus EPS$0.42
Beat/MissBeat by +$0.10
One Year Ago EPS$0.35
CON Q2 2026 Revenue Results
Actual Revenue$606.03M
Expected Revenue$591.75M
Beat/MissBeat by +$14.28M
YoY Revenue Growth+10.03%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
CON Upcoming Earnings
Concentra Group Holdings Parent, Inc.'s next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
CON Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call delivers a broadly positive message: robust top-line growth (10% revenue increase), notable margin expansion (EBITDA +22.5% and ~240 bps improvement), strong cash generation (operating cash flow and free cash flow roughly doubled YoY), successful acquisitions (Pivot/Nova ahead of underwriting), and updated, higher 2026 guidance. Manageable lowlights include comparability benefits from prior-year one-offs, expected moderation toward long-term visit growth, seasonality affecting margins, remaining debt/leveraging goals, and limited short-term contribution from new de novos. Overall, the strengths materially outweigh the risks and caveats discussed.Company Guidance
Revenue Growth
Total company revenue of $606.0M in Q2 2026, up 10.0% YoY; core revenue excluding Pivot was $589.1M, up 8.0% YoY.
Visit Volume Momentum
Total occupational health center visits averaged >56,000 visits/day in Q2, up 2.6% YoY; work comp visits/day +3.7% YoY; employer services visits +1.8% YoY.
Rate-per-Visit Improvement
Revenue per visit grew 4.6% YoY in Q2 (work comp +4.9%, employer services +3.2%); company expects rate growth to average closer to ~3% for the remainder of the year.
Strong Profitability and Margin Expansion
Adjusted EBITDA $140.9M vs $115.0M prior year (up 22.5%); adjusted EBITDA margin expanded ~240 bps from 20.9% to 23.3% YoY.
Earnings and EPS Growth
Adjusted net income attributable to company $66.7M and adjusted EPS $0.52 in Q2 2026, ~40% growth vs prior year adjusted net income $47.7M and EPS $0.37.
Onsite Health Segment Acceleration
Onsite Health reported revenue $38.8M, up 72.1% YoY; excluding Pivot acquisition impact, Onsite organic growth was +27.9% YoY, with a robust pipeline.
Cash Flow and Leverage Progress
Operating cash flow $135.2M (Q2 2026) vs $88.4M prior year; free cash flow $121.0M vs $63.2M prior year. Net leverage fell to just under 3.0x from 3.4x at Q1-end, ahead of schedule.
Raised 2026 Guidance and Capital Actions
Raised 2026 revenue guidance by $50M to $2.325B–$2.375B; adjusted EBITDA range raised to $485M–$495M; free cash flow to $220M–$240M. Declared quarterly dividend $0.0625/share and repurchased ~424k shares (~$11M) in Q2.
Acquisitions and De Novo Growth
Pivot and Nova acquisitions performing ahead of underwriting. Opened new de novo center in Phoenix in Q2 and subsequent centers in Boise (first in Idaho, bringing presence to 42 states) and Kansas City; targeting 8–10 de novos in 2026 and double-digit new sites in 2027.
Cost Efficiency Improvements
Cost of services improved to 68.3% of revenue in Q2 from 70.7% prior-year quarter; adjusted G&A (ex add-backs) 8.4% of revenue vs 8.5% prior year, driven by staffing efficiencies and synergy realization.
CON Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed